Skip Navigation

European Heart Journal 2003 24(18):1699; doi:10.1016/S0195-668X(03)00370-1
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Van der Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van der Werf, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letters to the Editor

Reply: Lack of a Rationale for the Task Force recommendation regarding Re-administration of Streptokinase

F. Van der Werf, Chairman, ESC Task Force on the Management of Acute Myocardial Infarction on behalf of the Task Force members

E-mail address: Frans.VandeWerf@uz.kuleuven.ac.be

The first 10% of the full text of this article appears below.

Dr Thimme questions the task force recommendation not to re-administer streptokinase (or anistreplase) in case of re-infarction.

Re-infarction due to re-occlusion of a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?